Omeprazol Hikma (Omeprazole)

Omeprazol Hikma is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation.
• Peptic ulcer disease: supports ulcer healing by maintaining a low‑acid environment.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.
• Helicobacter pylori eradication regimens (as adjunct): enhances the effectiveness of antibiotic therapy by reducing gastric acidity.
• NSA‑induced gastropathy prophylaxis: lowers risk of ulcer formation in patients requiring long‑term NSAID therapy.

• Omeprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acid secretion, allowing the gastric mucosa to heal and maintain a higher pH environment.

Adverse reactions to omeprazole are generally mild and dose‑dependent, but serious events can occur.

Common Side Effects

• Headache: mild, transient headache reported in clinical use.
• Diarrhea: loose stools occurring in a minority of patients.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort or cramping.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis linked to altered gut flora.
• Vitamin B12 deficiency: long‑term use may impair absorption.
• Hypomagnesemia: low serum magnesium with prolonged therapy.
• Acute interstitial nephritis: rare kidney inflammation.
• Stevens‑Johnson syndrome: severe skin reaction, extremely uncommon.
• Fracture risk: possible increase in hip, wrist or spine fractures with long‑term use.

When prescribing Omeprazol Hikma, clinicians should consider several safety aspects.

• Assess renal and hepatic function: adjust use in severe impairment.
• Review long‑term therapy need: limit duration when possible to reduce risk of nutrient deficiencies.
• Monitor for infection signs: be alert to Clostridioides difficile symptoms.
• Evaluate concomitant medications: consider potential for altered drug absorption.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation parameters.
• Digoxin: higher serum levels possible, observe for toxicity.
• Methotrexate (high dose): reduced clearance, watch for toxicity.
• Phenytoin: decreased plasma concentrations, may require dose adjustment.